NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Using the radioactive drug lutetium dotatate as the first treatment for faster-growing neuroendocrine tumours, rather than saving it for later, nearly tripled the time without progression compared with high-dose octreotide.
Overview
Open-label phase 3 trial of 226 patients with newly diagnosed, somatostatin-receptor-positive grade 2-3 (Ki-67 10-55%) advanced gastroenteropancreatic neuroendocrine tumours randomised 2:1 to four cycles of 177Lu-dotatate plus octreotide LAR 30 mg or high-dose octreotide LAR (60 mg). Primary endpoint was PFS by blinded review.
Median PFS was 22.8 vs 8.5 months (HR 0.28) with an objective response rate of 43% vs 9%. Following NETTER-1 (which established lutetium dotatate in progressive midgut tumours), it moved radioligand therapy to the first line for higher-grade disease, where somatostatin analogues alone are weak.
- Median PFS 22.8 vs 8.5 months; HR 0.28 (95% CI 0.18-0.42).
- Objective response 43.0% vs 9.3%.
- Benefit consistent in grade 2 and grade 3 tumours and in pancreatic and small-bowel primaries.
- Grade 3 or higher adverse events about 35% vs 28%; no cases of treatment-related myelodysplasia or leukaemia at the primary analysis.
- Overall survival data immature; crossover to lutetium dotatate was permitted at progression.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
- Comparator was high-dose octreotide, which has limited anti-proliferative activity in grade 2-3 tumours.
- Overall survival not yet shown; crossover will make it hard to demonstrate.
- Long-term risks of earlier radioligand exposure (marrow, kidney, secondary leukaemia) require follow-up.
- Requires somatostatin-receptor PET and nuclear medicine capacity; grade 3 tumours with Ki-67 above 55% were excluded.
Similar pages
not linked directly; found by shared links- TermPRRT (peptide receptor radionuclide therapy)
Shares Grade 3 well-differentiated neuroendocrine tumour, Dosimetry, Theranostics, Pancreatic neuroendocrine tumours.
- TrialCOMPETE
Shares Jonathan R. Strosberg, Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- InstitutionErasmus MC Cancer Institute
Shares Theranostics, Novartis, Somatostatin receptor 2, Lutetium-177 dotatate.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Lutetium-177 dotatate.
- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Lutetium-177 dotatate.
- TrialNETTER-1
Shares SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Novartis.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Dosimetry, Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Neuroendocrine tumours.